Evidence map›Paper›PMID 42084215›Full record

ArticleCancer research2026

Cancer-Associated Fibroblasts Promote Epithelial-Mesenchymal Transition and Classical to Basal Subtype Shift in Pancreatic Cancer.

Kylie Belanger, Samantha Guinn, Brayan Perez, Yeonju Cho, Joseph A Tandurella, Mili Ramani, Jae W Lee, Daniel J Zabransky, Emma Kartalia, Jignasha Patel and 29 more

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Kylie Belanger *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1613-8533
Samantha Guinn *Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4558-8915
Brayan PerezDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0005-9118-0995
Yeonju ChoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-3983-8337
Joseph A TandurellaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5806-6681
Mili RamaniDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-6714-691X
Jae W LeeConvergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0735-5707
Daniel J ZabranskyDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8184-3346
Emma KartaliaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0000-6891-0498
Jignasha PatelDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0003-1360-7709
Haley ZlomkeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-3544-6841
Norman G NicolsonDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9986-6327
Nicole E GrossDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-8936-207X
Sarah M ShinDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7658-5899
Benjamin C BarrettDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0005-2839-6806
Samantha SunDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0006-9890-8309
Nicholas SunDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0009-9153-9653
Ethan FirthDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0004-6557-1549
Alexei G HernandezDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-6044-2631
Erin M CoyneDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0393-6600
Courtney D CannonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0008-7720-8703
Eunji MoonDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0009-0007-1156-5735
Soren CharmsazDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-9148-9870
Ludmila DanilovaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2813-3094
James M LeathermanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-1721-2128
Melissa R LymanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-0091-0413
Jacob T MitchellDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-5370-9692
Lei ZhengDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-4163-2541
Michael G GogginsDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-4286-2296
Kelly J LafaroDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7070-7269
Jin HeDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-9149-2247
Christopher R ShubertDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0001-6472-2350
William R BurnsDepartment of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7634-9730
Elana J FertigDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3204-342X
Luciane T KagoharaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1706-0950
Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-3841-6549
Richard A BurkhartConvergence Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-1087-0870
Won Jin HoDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0003-2644-5086
Jacquelyn W ZimmermanDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.ORCID 0000-0002-7775-2943

Funding

Transforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI ANDERS, ROBERT A. · 2021 to 2025
$12.7M
Informing mechanistic rules of agent-based models with single-cell multi-omicsU24CA284156 · NCI · TRUSTEES OF INDIANA UNIVERSITY · PI Elana Fertig, Paul T Macklin · 2024 to 2026
$2.3M
Personalized preclinical models in pancreas cancer: a tractable approach to precision medicineK08CA248710 · NCI · JOHNS HOPKINS UNIVERSITY · PI BURKHART, RICHARD ANDREW · 2020 to 2024
$1.3M
Single-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2M
Mass Cytometer CyTOF XT for Single-Cell BiologyS10OD034407 · OD · JOHNS HOPKINS UNIVERSITY · PI HO, WON JIN · 2024 to 2024
$499k
Charles and Margaret Levin Family FoundationDana & Albert R. Broccoli Charitable FoundationLustgarten Foundation (Lustgarten)MacMillan Pathway to Independence AwardMaryland Cancer Moonshot Research GrantMD Anderson GI SPORENational Cancer Institute (NCI) K08CA248710National Cancer Institute (NCI) P01CA247886National Cancer Institute (NCI) S10OD034407National Cancer Institute (NCI) U01CA253403National Cancer Institute (NCI) U24CA284156NCI NIH HHS K08 CA248710NCI NIH HHS P01 CA247886NCI NIH HHS U01 CA253403NCI NIH HHS U24 CA284156NIH HHS S10 OD034407Passano Foundation Clinician Scientist AwardReichenberg and Semida Foundation
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) carries an extremely poor prognosis, in part resulting from cellular heterogeneity that supports overall tumorigenicity. Cancer-associated fibroblasts (CAF) are key determinants of PDAC biology and response to systemic therapy, and multiple CAF subtypes have been defined. However, defining the effects of patient-specific CAF heterogeneity and plasticity on tumor cell behavior is required to better characterize the role of CAFs in PDAC. In this study, we used multiomic analyses to characterize the tumor microenvironment (TME) in tumors from patients undergoing curative-intent surgery for PDAC. In these same patients, matched tumor organoid and CAF lines were established to functionally validate the impact of CAFs on the tumor cells. CAFs promoted epithelial-mesenchymal transition and a switch in tumor cell classification from classical to basal subtype. Furthermore, CAF-specific interleukin 8 functioned as a modulator of tumor cell subtype. Finally, neighborhood relationships between tumor cells and T cell subsets were defined, demonstrating a distinct spatial coordination among CAF and tumor cell subtypes. Overall, this study provides data supporting CAF signaling as a regulator of the cellular and behavioral heterogeneity in the PDAC TME. These findings can be used to explore rational approaches to improve therapies for this difficult-to-treat disease. SIGNIFICANCE: Multidimensional analyses highlight the diverse role of cancer-associated fibroblasts in influencing cells in the tumor microenvironment and provide a platform for evaluating emerging therapeutic approaches and studying mechanisms dictating tumor behavior.

Indexed as

Cancer-Associated FibroblastsCarcinoma, Pancreatic DuctalEpithelial-Mesenchymal TransitionPancreatic NeoplasmsCell Line, TumorHumansInterleukin-8Signal TransductionTumor MicroenvironmentInterleukin-8

Identifiers

PMID42084215
PMCPMC13245478

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.